David Davidson, M.D., is the former chief medical officer for Bluebird bio, a leading biotechnology company developing innovative gene therapies. He announced his departure from the company in March 2021, but will remain on as a consultant for six months to assist with the transition of his duties.
Dr. Davidson joined Bluebird as its CMO in 2012. He had previously spent eight years at Genzyme, serving as a senior medical director leading clinical research for programs across wide-ranging therapeutic areas. His most recent work was as the medical leader for the company’s gene therapy and Pompe disease enzyme replacement therapy (ERT) programs.
Throughout his career, Dr. Davidson has worked on various commercial products, such as Fabrazyme, Myozyme, and Lumizyme—all ERTs. He also played a key role in creating the new drug application resulting in the approval of cholesterol drug, Welchol.
Before Genzyme, he served as a medical director for GelTex Pharmaceuticals Inc.
Additionally, Dr. Davidson completed infectious disease fellowships through the Harvard Longwood Combined Infectious Diseases Program. He also completed an internal medicine internship, residency, and an endocrinology fellowship with the University of Chicago Hospitals.
Dr. Davidson earned his bachelor’s degree at Columbia University and his M.D. at the New York University School of Medicine.
What is David Davidson's net worth?
The estimated net worth of David Davidson is at least $37,836.96 as of October 2nd, 2020. Dr. Davidson owns 39,703 shares of bluebird bio stock worth more than $37,837 as of April 19th. This net worth approximation does not reflect any other assets that Dr. Davidson may own. Learn More about David Davidson's net worth.
How do I contact David Davidson?
Has David Davidson been buying or selling shares of bluebird bio?
David Davidson has not been actively trading shares of bluebird bio over the course of the past ninety days. Most recently, David Davidson sold 64 shares of the business's stock in a transaction on Friday, October 2nd. The shares were sold at an average price of $52.77, for a transaction totalling $3,377.28. Following the completion of the sale, the insider now directly owns 39,703 shares of the company's stock, valued at $2,095,127.31. Learn More on David Davidson's trading history.
Who are bluebird bio's active insiders?
Are insiders buying or selling shares of bluebird bio?
During the last year, insiders at the biotechnology company sold shares 8 times. They sold a total of 34,859 shares worth more than $107,838.66. The most recent insider tranaction occured on February, 5th when insider Thomas J Klima sold 2,714 shares worth more than $2,442.60. Insiders at bluebird bio own 2.1% of the company.
Learn More about insider trades at bluebird bio. Information on this page was last updated on 2/5/2024.
